MOTS-c Excess Dose: What to Record and Where to Get Help

Start With Triage, Not a Dose Calculator

The legacy version of this page offered a home glucose schedule, carbohydrate instructions, a presumed half-life, a mouse-to-human “high-dose” conversion, and medication-specific treatment thresholds. None came from a human MOTS-c toxicology study. That kind of precision is especially unsafe when the product's identity and concentration may be uncertain.

Call emergency services immediately if the person collapses, has a seizure, has trouble breathing, or cannot be awakened. In the United States, Poison Control provides case-specific exposure guidance online or at 1-800-222-1222.

Its practical advice is direct:

“Don’t wait for symptoms to develop. Get free, expert help right away!”

The issuer is the National Capital Poison Center, whose service connects callers with nurse or pharmacist poison specialists and medical-toxicology backup. The quote appears on “Get help online or by phone,” under the immediate-help instructions. It applies to suspected poison exposures generally; it is not evidence that MOTS-c has a known poison profile.

Why the Amount Alone Cannot Answer the Question

FDA's July 2026 review found no acute-toxicity studies of MOTS-c free base or acetate, no clinical pharmacokinetic studies, and no human exposure data sufficient to evaluate safety in compounded products. It also raised concerns about aggregation and peptide-related impurities.

That leaves at least four unknowns in a suspected excess exposure:

1. What was in the vial? The stated peptide, salt form, excipients, and impurities may be uncertain.
2. What concentration was present? A label or reconstitution calculation can be wrong.
3. What amount entered the body? Drawn volume, residual vial volume, route, leakage, and timing matter.
4. What else changes risk? Symptoms, age, body size, pregnancy, health conditions, medicines, supplements, and other exposures affect triage.

A mouse dose does not resolve these questions. Animal efficacy experiments are not human overdose thresholds, and cross-species arithmetic cannot establish a lethal dose or a safe observation window.

The Exposure Packet

Poison specialists make recommendations from specifics. Gather what is available without delaying urgent care.

Bring or photograph the container when possible. Do not discard the vial, packaging, receipt, or preparation instructions before speaking with a poison specialist or clinician.

What Not to Do

• Do not take another dose to “balance” the exposure.
• Do not induce vomiting.
• Do not inject glucose, glucagon, insulin, or another medicine unless a qualified clinician or poison specialist directs it for the actual case.
• Do not rely on a peptide calculator to decide that the exposure is safe.
• Do not assume no symptoms means no action is needed.
• Do not diagnose every symptom as an AMPK effect; the product layer may be more important.

The delayed-side-effect audit explains why symptom timing cannot prove causality. The rare-but-serious review separates human observation from theoretical mechanism, and the MOTS-c older-adult safety page addresses age-related uncertainty without inventing thresholds.

Product Error and Molecule Excess Are Different Problems

An excess volume of correctly identified material is one scenario. A mislabeled, over-concentrated, contaminated, degraded, or aggregated product is another. They may look identical at first.

FDA says poor compounding practices can produce contamination or too much or too little active ingredient. Because compounded drugs are not FDA-approved, FDA does not verify their safety, effectiveness, or quality before marketing. These general compounding facts do not establish that a particular vial is defective; they explain why traceability belongs in the assessment.

If a clinician suspects an adverse event or product-quality problem, FDA's MedWatch program accepts reports involving unapproved and compounded products. Reporting does not prove causation, but it preserves a signal and the product details needed to investigate it.

Why the Current Trial Does Not Supply an Overdose Protocol

NCT07505745 is a recruiting Phase 2a trial with no results posted. Its public record describes controlled study administration and safety follow-up, not overdose management. Even after results appear, a planned trial dose will not automatically define:

• the toxicity of a larger exposure;
• the risk from a different formulation;
• the effect of impurities or concentration errors;
• an observation duration for an individual case; or
• a specific antidote.

Those questions require toxicology, pharmacokinetics, case data, and product characterization.

The Responsible Bottom Line

This page can offer a triage path and an exposure record. It cannot responsibly offer a lethal dose, “safe double dose,” home glucose protocol, clearance time, or treatment algorithm.

Medical review of this revision is pending. Poison Control, FDA, trial investigators, and study authors do not endorse MOTS-c, HealthRX.com, or this page.